FDA Awards Fast Track Designation to Staphylococcus aureus Vaccine Candidate
The FDA granted fast track designation to LimmaTech's LBT-SA7 vaccine candidate, designed to prevent skin and soft tissue infections caused by Staphylococcus aureus. The vaccine aims to neutralize toxins from the bacteria, addressing rising antibiotic resistance. A phase 1 clinical trial will assess its safety and immunogenicity, with results expected in 2025.
Highlighted Terms
Related News
FDA Awards Fast Track Designation to Staphylococcus aureus Vaccine Candidate
The FDA granted fast track designation to LimmaTech's LBT-SA7 vaccine candidate, designed to prevent skin and soft tissue infections caused by Staphylococcus aureus. The vaccine aims to neutralize toxins from the bacteria, addressing rising antibiotic resistance. A phase 1 clinical trial will assess its safety and immunogenicity, with results expected in 2025.